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Abstract Osteoarthritis (OA) is a whole-joint disease
characterized by articular cartilage loss, tissue inflamma-
tion, abnormal bone formation and extracellular matrix
(ECM) mineralization. Disease-modifying treatments are
not yet available and a better understanding of
osteoarthritis pathophysiology should lead to the discovery
of more effective treatments. Gla-rich protein (GRP) has
been proposed to act as a mineralization inhibitor and was
recently shown to be associated with OA in vivo. Here, we
further investigated the association of GRP with OA min-
eralization–inflammation processes. Using a synoviocyte
and chondrocyte OA cell system, we showed that GRP
expression was up-regulated following cell differentiation
throughout ECM calcification, and that inflammatory
stimulation with IL-1b results in an increased expression of
COX2 and MMP13 and up-regulation of GRP. Impor-
tantly, while treatment of articular cells with c-
carboxylated GRP inhibited ECM calcification, treatment
with either GRP or GRP-coated basic calcium phosphate
(BCP) crystals resulted in the down-regulation of inflam-
matory cytokines and mediators of inflammation,
independently of its c-carboxylation status. Our results
strengthen the calcification inhibitory function of GRP and
strongly suggest GRP as a novel anti-inflammatory agent,
with potential beneficial effects on the main processes
responsible for osteoarthritis progression. In conclusion,
GRP is a strong candidate target to develop new thera-
peutic approaches.
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Introduction
Osteoarthritis (OA) is the leading form of degenerative
joint diseases [1] characterized by progressive loss of
articular cartilage, abnormal bone formation, tissue
inflammation and synovial proliferation, culminating in
pain, loss of joint function and disability [2, 3]. At the
cellular level, OA results from abnormal chondrocyte dif-
ferentiation into a hypertrophic phenotype and impairment
of the homeostatic balance between synthesis and degra-
dation of their extracellular matrix (ECM). This phenotype
is commonly associated with ECM mineralization that can
result from basic calcium phosphate (BCP) crystals depo-
sition [4] contributing to disease progression [5]. Crystal
deposition in OA is not unique for cartilage and has also
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been reported in the synovial fluid and membrane, where it
modulates inflammatory responses [6, 7]. The prevailing
theory is that proinflammatory and catabolic mediators,
such as nitric oxide, cytokines, prostaglandins and matrix
metalloproteinases (MMPs) [5, 7, 8], are released from
cartilage into the synovial space, and that the presence of
calcium crystals amplifies the production of such media-
tors, contributing to joint inflammation and cartilage
degradation [5, 7].
Osteoarthritis prevention and treatment are still limited
impelling the need to identify novel targets and biomarkers
for prevention, therapeutics and prophylactic treatment [9].
An interesting candidate is vitamin K, which is critical for
preventing soft tissue mineralization [10, 11]. Moreover,
vitamin K was also suggested as a protective agent against
inflammation [12]. Vitamin K is an essential cofactor for
the post-translational modification of vitamin K-dependent
proteins (VKDPs), where specific glutamic acid (Glu)
residues can be modified to calcium binding c-carboxyg-
lutamic acid (Gla) residues [13]. While subclinical vitamin
K levels have been associated with an increased risk of OA
development [14, 15], several VKDPs, such as matrix Gla
protein (MGP), osteocalcin (OC), and recently Gla-rich
protein (GRP), have been associated with the disease.
Moreover, the presence of undercarboxylated OC in serum,
resultant of vitamin K insufficiency, is considered as a risk
marker for OA [16]. Importantly, impaired c-carboxylation
of MGP has been associated with increased mineralization
of osteoarthritic cartilage [15], whereas also levels of
undercarboxylated MGP in synovial fluid and serum were
recently suggested as a potential inflammatory marker of
arthritis [17].
GRP is the newest member of the VKDP family. It was
first identified in sturgeon calcified cartilage and charac-
terized by the presence of 15 putative Gla residues in man
[18], but its function and molecular mechanisms of action
remain to be further clarified. GRP has been suggested to
act as a modulator of calcium availability in the ECM [19,
20], and an inhibitor of calcification in the cardiovascular
system [21]. However, conflicting data, particularly asso-
ciated to its function in mouse skeletal tissues, reinforce the
need for additional characterization of GRP potential
association to human pathological conditions such as OA.
While GRP-deficient mice did not reveal evident pheno-
typic alterations in bone and cartilage [22], zebrafish
knockdown studies highlighted the essential role of GRP in
skeletal development and calcification [23]. Although GRP
has been shown to function as a negative regulator of
osteogenic differentiation [24, 25] and to be down-regu-
lated by bone morphogenetic protein 2 (BMP-2) in
chondrogenic cells [24], recent data suggested that GRP is
up-regulated by both runt-related transcription factor 2
(Runx2) and osterix (Osx) stimulating osteoblast
differentiation and nodule formation [26]. Our previous
studies revealed a differential pattern of GRP gene
expression and protein accumulation between control and
osteoarthritic human articular cartilage and synovial
membrane tissues. Furthermore, we verified that GRP
accumulation was not restricted to sites of ectopic calcifi-
cation [27], suggesting the involvement of this VKDP in
cell-mediated processes other than ECM calcification in
OA.
In this context, and to further understand the relevance
of GRP for OA etiology, we used an in vitro cell system to
study the relationship between GRP and the mineralization
and inflammatory processes involved in OA development
and progression. Our results demonstrate the involvement
of GRP in calcification processes associated to OA-affected
tissues, supporting a previously proposed role for GRP as a
novel biomarker for calcification-related diseases. More-
over, we describe, for the first time, a new role for GRP in
inflammatory events, and propose this VKDP as a novel
factor linking the two main pathological processes
responsible for OA development and progression.
Materials and methods
Biological material and sample processing
Knee articular cartilage and synovial membrane samples
were obtained from osteoarthritic patients who had
undergone arthroplasty surgeries. Tissues were collected in
Dulbecco’s Modified Eagle’s Medium (DMEM, Invitro-
gen, Carlsbad, CA, USA) for cell culture preparation and in
formalin for histological processing, followed by paraffin
embedding as described [28]. This study was approved by
the ethics committees of the hospitals involved, and written
informed consent was obtained from all the participants.
Cell culture development and maintenance
Tissues, both articular cartilage and synovial membrane,
were digested overnight with 2 mg/mL collagenase in
DMEM at room temperature (RT). Fragments were washed
three times with DMEM, placed in 24-well plates, and
cultured in the same medium supplemented with 1 % (v/v)
penicillin–streptomycin, 1 mM L-glutamine and 10 % (v/
v) fetal bovine serum (FBS), at 37 C in a humidified
atmosphere with 5 % CO2. OA-derived chondrocytes (OA-
HAC, osteoarthritic human articular chondrocytes) and
synoviocytes (OA-HFLS, osteoarthritic human fibroblast-
like synoviocytes) were allowed to migrate from fragments
and adhere to wells for approximately 2 weeks, then col-
lected using trypsin solution (Invitrogen) for cell passage,
and placed into new plate dishes with fresh media. Cultures
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were routinely sub-cultured (1:2) at early confluence by
trypsinization. Cellular proliferation measurements indi-
cated higher growth performance using advanced DMEM
(Invitrogen) supplemented with 1 % (v/v) penicillin–
streptomycin, 1 mM L-glutamine and 10 % (v/v) FBS
when compared with DMEM. Therefore, advanced DMEM
was used throughout the study, in all cell lines. Cells used
in the experiments were between passages 4 and 14.
Control primary chondrocytes (NHAC, Lonza, Visp,
Switzerland) and synoviocytes (HFLS, ECACC, Sigma-
Aldrich, St. Louis, MO, USA) were commercially
obtained. A second set of OA and control-derived primary
chondrocytes cultures (OAC and NC, respectively) and
primary synoviocytes cultures (SOAR and SNR, respec-
tively) were obtained using well-defined methodology [29,
30], and used to confirm the results obtained with of the
first set of cells.
Cellular proliferation measurement
Cells were seeded in 96-well plates at 2 9 104 cells/well
and cultured in DMEM and advanced DMEM supple-
mented with 1 % (v/v) penicillin–streptomycin, 1 mM L-
glutamine and 10 % (v/v) FBS and both culture conditions
were analyzed for cell viability at appropriate times using
the CellTiter 96 cell proliferation assay (Promega, Madi-
son, WI, USA), following manufacturer’s instructions. Cell
viability of cultures supplemented with 5.4 mM CaCl2,
500 ng/mL of sturgeon cGRP or human recombinant
ucGRP [20], 5 ng/mL of interleukin 1b (IL-1b) or 100 lg/
mL of BCP crystals (prepared as described below) was also
determined using the same procedure.
RNA extraction, cDNA amplification
and quantitative real-time PCR (qPCR)
Total RNA was isolated from cell cultures as described by
Chomczynski and Sacchi [31]. RNA concentration was
determined by spectrophotometry at 260 nm and quality
evaluated by agarose-denaturing gel electrophoresis. Five
hundred ng of total RNA was treated with DNase RQ-I
(Promega) and reverse transcribed using Moloney-murine
leukemia virus reverse transcriptase (MMLV-RT, Invitro-
gen), RNase Out (Invitrogen), and an oligo(dT) adapter
(ACGCGTCGACCTCGAGATCGATG(T)13), according
to manufacturer’s recommendations.
Quantitative real-time PCR reactions were performed
using the StepOne system (Life Technologies, Carlsbad,
CA, USA), SsoFast Eva Green Supermix (Bio-Rad, Rich-
mond, CA, USA), 300 nM of forward and reverse gene-
specific primers (final concentration) for genes of interest
(Online Resource 1) and a 1:5 dilution of reverse-tran-
scribed RNA reaction mixture. The following PCR
conditions were used: initial denaturation/enzyme activa-
tion step at 95 C for 5 min, 50 cycles of amplification
(one cycle is 30 s at 95 C and 15 s at 66 C); 18S was
used as a housekeeping gene to normalize expression.
Immunofluorescence and immunohistochemistry
Immunofluorescence (IF) was performed in sub-confluent
cultures, seeded the previous day. Cells were washed with
PBS and fixed for 10 min in 4 % (v/v) paraformaldehyde.
Fixed cells were incubated at RT for 1 h with CTerm-GRP
(10 lg/mL, GenoGla Diagnostics, Faro, Portugal), mouse
monoclonal cGRP (10 lg/mL, GenoGla Diagnostics) or
mouse monoclonal ucGRP [20] (7.3 lg/mL, VitaK BV,
Maastricht, The Netherlands) primary antibodies, followed
by incubation for 1 h, at RT with Alexa488 or Alexa594
labeled secondary antibodies (Invitrogen), respectively.
Fluorescence images were obtained using an Axio Imager
Z2 microscope (Zeiss, Jena, Germany) equipped with a
digital camera and AxioVision imaging software. Final
images were processed using Image J Version 1.41 m.
Immunohistochemistry (IHC) was performed in paraffin
tissue sections of osteoarthritic synovial membrane as
described [32]. Antigen retrieval was performed by boiling
tissue sections in 0.2 % (v/v) citric acid pH 6.0, followed
by endogenous peroxidase and nonspecific antibody
blocking and incubations with CTerm-GRP (5 lg/mL) or
mouse monoclonal cluster of differentiation 45 (CD45,
2 lg/mL, Santa Cruz Biotechnology) primary antibodies.
Peroxidase activity was detected using the respective per-
oxidase-conjugated secondary antibodies (Sigma-Aldrich)
and ImmPACT NovaRED substrate kit (Vector laborato-
ries Ltd., Peterborough, UK). Sections were counterstained
with hematoxylin.
ECM mineralization assay
To induce mineralization of the ECM, confluent cultures
grown in advanced DMEM were supplemented with CaCl2
to a final calcium concentration of 5.4 mM. The experi-
ment was performed during 3 weeks with media changes
twice a week and each week set as an experimental time
point (T0–T3). Mineral content was detected by von Kossa
staining as described [33]. Formation of mineralized nod-
ules in the ECM was observed under a Motic AE 31
inverted light microscope.
To analyze the effect of GRP on mineralization, con-
fluent chondrocytes and synoviocytes were grown for
3 weeks in advanced DMEM under mineralizing condi-
tions supplemented with 500 ng/mL of cGRP or ucGRP
and compared with respective controls. At appropriate
times, calcium/protein ratios were determined, as described
below.
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Calcium and total protein quantification
At appropriate times, cell cultures grown in control or
mineralizing conditions were washed twice with PBS and
mineral was dissolved overnight with 1 M HCl, at 4 C.
ECM calcium concentration was then determined using a
commercially available kit (Calcium assay CA-590, Ran-
dox, Co. Antrim, UK). Equimolar amounts of NaOH
containing 5 % (w/v) SDS were then used to neutralize the
remaining HCl-mineral phase and determine total protein
concentration using the micro BCA protein assay kit
(Thermo Scientific, Waltham, MA, USA). Results are thus
presented as calcium/protein ratios.
Inflammation assay
Confluent chondrocytes and synoviocytes were cultured in
advanced DMEM or supplemented with 500 ng/mL of
cGRP, 500 ng/mL of ucGRP or 2 lM dexamethasone
(DXM) during 24 h. Cells were washed twice with PBS
and media were changed for advanced DMEM supple-
mented with 5 ng/mL of IL-1b for 72 h. At appropriate
times, cell media were collected for prostaglandin E2
(PGE2) quantification and cells washed twice with PBS for
RNA extraction. PGE2 measurement was achieved using
an available ELISA kit (Thermo Scientific) following
manufacture’s protocol.
Protein mineral complex (PMC) assay
BCP crystals were produced based on a previously
described procedure, and the resulting crystals were
washed three times with Milli-Q water and reduce to fine
particles by sonication (Vibra-cell apparatus, Sonics &
Materials, Inc., Newtown, MA, USA) [21, 34]. PMCs were
prepared by incubating BCP crystals (100 lg) in Milli-Q
water for 30 min at 37 C with approximately 500 ng of
cGRP or ucGRP [21]. Pellets containing PMCs or BCP
crystals were added to confluent chondrocytes and syn-
oviocytes and assayed for 72 h (controls consist of culture
medium only). At appropriate times, cells were washed
twice with PBS prior to RNA extraction and cell media
were collected for PGE2 measurement as previously
described.
Statistical analysis
Data are presented as mean (n[ 2) ± standard error.
Ordinary one-way ANOVA was used for comparisons
within the same group. Multiple t tests were used for
comparison between two groups. For two groups submitted
to a variable, significance was determined using two-way
ANOVA and multiple comparisons were achieved with the
Tukey’s test. Statistical significance was defined as
P B 0.05 (*), P B 0.005 (**) and P B 0.0005 (***).
Results
GRP and genes involved in the c-carboxylation
machinery are associated with osteoarthritis
The association of GRP with OA was analyzed on chon-
drocyte and synoviocyte primary cell cultures, the two
main cell types involved in OA pathology. Human articular
chondrocytes and fibroblast-like synoviocytes, either con-
trol (NHAC and HFLS, respectively) or derived from OA
patients (OA-HAC and OA-HFLS, respectively), were
characterized by gene expression profiling of differentia-
tion and known OA-related markers, and correlated with
the expression of GRP, MGP, and genes related to c-car-
boxylation processing. The obtained results showed higher
levels of OC, cartilage oligomeric matrix protein (COMP)
and collagen type X (Col10a1), and lower levels of colla-
gen type II (Col2a1) in OA-HAC cells (Fig. 1a),
confirming an osteoarthritic chondrocyte phenotype. Also,
OA-HFLS cells, exhibited higher levels of the OA-asso-
ciated gene markers OC, MMP13 and CD68, and lower
vimentin expression (Fig. 1a).
GRP and MGP were found to be up-regulated in both
OA-derived cultures, OA-HAC and OA-HFLS, while c-
carboxylase (GGCX) and vitamin K epoxide reductase
(VKOR) were shown to be expressed at lower levels than
in control-derived cells (Fig. 1b), suggesting an increased
production of VKDPs, but an impaired c-carboxylation
capacity in OA-derived cells. To access GRP c-carboxy-
lation status, the protein accumulation pattern was
analyzed in OA and control cells by IF using the confor-
mation-specific monoclonal antibodies cGRP and ucGRP,
and the polyclonal CTerm-GRP recognizing total GRP
(Fig. 2). In concordance with previously reported data from
osteoarthritic cartilage and synovial membrane tissue
samples [27], both cGRP and ucGRP were detected in
pathological and control chondrocyte cells, while only
ucGRP was found associated with the OA-HFLS cells.
Overall, the results indicate that OA-derived cells
showing osteoarthritic gene expression patterns have GRP
up-regulation and indications of a reduced c-carboxylation
capacity.
Calcification and cell differentiation in OA are
correlated with GRP expression
The calcification capacity of both NHAC/OA-HAC and
HFLS/OA-HFLS cells was assessed by von Kossa staining
(Fig. 3a) and by calcium quantification of the mineral
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deposited in the ECM (Fig. 3b). The results showed that all
cell cultures were able to mineralize their ECM, although
after the 3 weeks of treatment higher calcium levels and
mineral deposition were found in chondrocyte-derived
cultures when compared to synoviocytes (Fig. 3a, b, T3).
Significant differences in calcium quantification between
OA and control chondrocytes were evident at week 1 (T1),
although during subsequent weeks the differences gradu-
ally disappeared.
The expression patterns of gene markers for cell dif-
ferentiation and mineralization were simultaneously
investigated, in control and OA-derived primary cells to
determine their correlation with calcification. After the first
week of treatment (T1), OA-HAC cells showed higher
expression levels of GRP, MGP, OC, Osx and Col10a1,
and lower levels of Col2a1, compared to control NHAC
cells (Fig. 4a). The progressive down-regulation of Col2a1
in parallel with the up-regulation of Col10a1, Osx and OC
throughout the treatment in both cultures is consistent with
differentiation occurring in chondrocytes towards a
hypertrophic phenotype and ECM calcification.
The most significant differences between control and
OA-derived cells were observed at T1, suggesting that,
under calcification stimulating conditions the already
altered phenotype of primary OA-derived cells induces a
faster response. However, at T3 most of the gene markers
were found similarly expressed, in concordance with the
similar levels of calcification obtained for both cultures
(Fig. 3b). Notably, levels and patterns of GRP and Osx
gene expression were found similarly up-regulated in OA-
derived chondrocytes, throughout mineralization treatment,
with higher levels in OA-derived cells at all-time points. In
synoviocytes, vimentin down-regulation and CD68 up-
regulation were observed during induced calcification, in
both OA-derived and control cells; this is suggestive for a
phenotypic change from fibroblast-like synoviocytes
towards a macrophage lineage, while GRP, MGP, OC and
osteopontin (OPN) were gradually up-regulated throughout
mineralization, with only minor differences observed
between OA-derived and control cells (Fig. 4b).
Carboxylated GRP is able to reduce mineral
deposition in articular cells ECM
To determine the direct effect of GRP in ECM mineral-
ization of chondrocytes and synoviocytes, and further
unveil the relevance of its c-carboxylation status, cells
cultured under control and mineralizing conditions were
supplemented with ucGRP or cGRP. Cell proliferation
assays were performed for both GRP protein forms to
Fig. 1 Characterization of control and osteoarthritic-derived (OA)
chondrocyte and synoviocyte cell cultures through gene expression
patterns determined by qPCR. a Expression of OA (OC, COMP and
MMP13) and differentiation (Cola2a1, Cola10a1, CD68 and vimen-
tin) gene markers in control (NHAC and HFLS) and OA-derived
(OA-HAC and OA-HFLS) chondrocytes and synoviocytes.
b Expression of VKDP-related genes (GRP, MGP, GGCX and
VKOR) in control and OA-derived chondrocytes and synoviocytes.
Values are relative to a reference sample (control cell culture) set to 1.
All experiments were repeated at least three times. Multiple t tests
were performed. Statistical significance was defined as P B 0.05 (*),
P B 0.005 (**) and P B 0.0005 (***)
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confirm that the treatment was not cytotoxic (data not
shown). The results showed that the addition of cGRP
significantly decreased mineral deposition after 3 weeks of
treatment, in both control (Fig. 5) or OA-derived (results
not shown) chondrocytes and synoviocytes, while no effect
was observed with ucGRP treatment.
GRP is associated with inflammatory events in OA
To study the interplay between mineralization and inflam-
matory events in OA, the inflammatory response of
chondrocytes and synoviocytes under mineralization condi-
tions was determined by analyzing the expression patterns of
inflammation markers. Increased expression of COX2 and
MMP13, throughout the time course indicated that a min-
eralization stimulus is able to trigger the inflammatory
response in both cells systems (Fig. 6a). Since in this model,
GRP was also found to be up-regulated with mineralization
treatment (Fig. 4), we have further studied the possible
relation between GRP and inflammation by inducing chon-
drocytes and synoviocytes with an inflammatory stimulus
and evaluating GRP expression pattern. A sharp rise in GRP
gene expression concomitant with an increase in COX2 and
MMP13 expression was obtained at 3 h after IL-1b
treatment (Fig. 6b). From 6 to 72 h of stimulation, the
expression of GRP and inflammatory gene markers had
progressively decreased until control levels. To evaluate the
association of GRP with inflammation in vivo, the presence
of GRP in osteoarthritic synovial membrane was determined
by IHC and the results showed co-localization of GRP with
CD45 positive cells, indicative of leucocytes (Fig. 6c–f).
GRP is a novel factor in the cross-talk
between calcification and inflammation processes
Since BCP crystals deposition has been associated with
inflammatory responses in OA, and GRP binding capacity
to calcium crystals has been previously reported [21],
chondrocytes and synoviocytes were treated with BCP
crystals and BCP crystals coated with either cGRP/ucGRP
(PMCs), during 72 h, to evaluate the inflammatory
response. Up-regulation of COX2 and MMP13 expression
in BCP-treated cells confirmed the inflammatory response
mediated by BCP crystals, both in synoviocytes and
chondrocytes cell systems, while treatment of cells with
non-cytotoxic doses of PMCs, containing either cGRP or
ucGRP, resulted in decreased COX2 and MMP13 expres-
sion (Fig. 7a). A corresponding significant reduction of
Fig. 2 Accumulation patterns of GRP protein forms in both control
(NHAC and HFLS) and OA (OA-HAC and OA-HFLS)-derived
chondrocytes and synoviocytes. Immunofluorescence imaging was
obtained for total GRP (CTerm-GRP), c-carboxylated (cGRP) and
undercarboxylated GRP (ucGRP) protein forms using specific anti-
bodies. Cell nuclei were stained with DAPI; scale bar represents
100 lm. All experiments were repeated at least twice
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PGE2 accumulation in cell media was detected after 72 h
of treatment with PMCs, when compared with cells treated
with BCP crystals (Fig. 7b). Altogether, our results showed
that GRP coating significantly diminished the inflamma-
tory reaction associated with BCPs, and point GRP as a
new mediator factor linking mineralization and inflamma-
tory processes.
GRP acts as an anti-inflammatory agent
in osteoarthritis
To determine if GRP had a direct effect on inflammatory
processes and if this response was dependent of its c-car-
boxylated state, chondrocytes and synoviocytes, stimulated
with IL-1b, were pre-treated with ucGRP/cGRP or DXM,
the latter used as a control anti-inflammatory agent. In both
cell systems stimulated with IL-1b, the treatment with
either ucGRP/cGRP, resulted in significant lower levels of
COX2 and MMP13 expression relative to non-treated cells
(Fig. 8a), indicating an anti-inflammatory effect of GRP.
To further confirm these results, PGE2 accumulation in cell
media after 24 h of pre-treatment with cGRP and ucGRP
(Fig. 8b) was measured, and the results showed lower
levels of PGE2 in media of cells pre-treated with both
protein forms relative to non-treated cells. Moreover, a
similar anti-inflammatory effect was observed in OA-HAC
and OA-HFLS cells. Notably, the ucGRP/cGRP effects on
COX2 and MMP13 expression were comparable with
levels obtained after 3 h of IL-1b stimulation in cells pre-
treated with DXM, particularly in chondrocytes (Online
Resource 2). The 3-h stimulation period corresponds with
the inflammatory peak response. These results strongly
suggest that GRP might be a powerful anti-inflammatory
agent in OA that can exert its function independent of its c-
carboxylation status.
Discussion
In this study, we demonstrate for the first time the
involvement of GRP, the most recently discovered VKDP,
in the two major molecular processes affecting
Fig. 3 In vitro ECM mineralization of control and OA-derived
chondrocytes and synoviocytes (NHAC and OA-HAC, and HFLS and
OA-HFLS, respectively). a Representative von Kossa staining at
week 3 (T3) in control or induced mineralizing conditions with
5.4 mM CaCl2 (Ca). Scale bar represents 100 lm. b Mineralization
rate was determined every week (T0–T3) through calcium quantifi-
cation normalized to protein levels. Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*) and P B 0.005 (**)
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osteoarthritis: mineralization and inflammation of articular
tissue. GRP appears to be functioning as an ECM miner-
alization inhibitor and as an anti-inflammatory agent, both
on chondrocytes and synoviocytes, the two main articular
cell types. Moreover, while GRP c-carboxylation was
shown to be essential for its calcification inhibitor effect, it
Fig. 4 Association of GRP with calcification and cell differentiation
in osteoarthritis. a Gene expression patterns of GRP, mineralization
(MGP, OC and Osx) and differentiation (Col2a1 and Col10a1)
markers during induced mineralization of chondrocytes (NHAC and
OA-HAC). b Gene expression patterns of GRP, mineralization (MGP,
OC and OPN) and differentiation (vimentin and CD68) markers
during induced mineralization of synoviocytes (HFLS and OA-
HFLS). Gene expression was determined every week during 3 weeks
(T0–T3). Gene expression values are relative to the reference sample
(control cell culture) and set to 1. Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*) and P B 0.005 (**)
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was apparently irrelevant for its anti-inflammatory action,
pointing to differential roles for undercarboxylated and
carboxylated GRP.
GRP gene expression was found to be up-regulated in
OA-derived chondrocytes and synoviocytes, and was
associated with higher levels of the calcification inhibitor
MGP and OA-related gene markers such as OC, COMP
and Col10a1. The results here obtained are in concordance
with our previous studies with biological samples, where
we showed an increase in GRP expression associated with
OA [27], and also with the higher demand of calcification
inhibitors, required to balance increased cell differentiation
and ECM calcification occurring in OA [4]. Moreover, c-
carboxylated GRP was shown to decrease calcification in
both chondrocytes and synoviocytes, and the increase in
GRP expression accompanied cell differentiation towards
ECM mineralization, in both cell systems. The up-regula-
tion of GRP during osteochondrogenic differentiation,
characterized by a decrease in Col2a1 and concomitant
increase in Col10a1, was recently shown during osteogenic
differentiation of MC3T3 cells, supporting the suggested
up-regulation of GRP gene by Osx [26]. Nevertheless,
previous studies have shown that GRP is repressed by
BMP2, a protein known to be responsible for Osx up-
regulation during osteogenesis [24]. These controversial
data emphasize that the molecular mechanism of GRP
action requires further clarification. Moreover, while GRP
was suggested to act as a stimulating factor in osteoblast
differentiation and nodule formation [26], previous data
have shown an impairment of osteogenic differentiation by
GRP [24, 25]. None of these studies have taken into con-
sideration the fact that GRP is a c-carboxylated protein,
and we have shown that although both forms, cGRP and
ucGRP, have mineral-binding capacity, only cGRP is able
to inhibit ECM calcification in the vascular system [21]. In
concordance, GRP knockdown in zebrafish resulted in
severe growth retardation and perturbance of skeletal
development, while warfarin treatment mimicked the GRP
knockdown phenotype, suggesting an essential role of c-
carboxylation for GRP function [23]. Our new data, using
GRP media supplementation in chondrocyte and synovio-
cyte cell cultures, strengthen the proposed calcification
inhibitory function of GRP and reinforce the importance of
its c-carboxylation status, probably acting by decreasing
calcium availability in the local environment, or changing
the dynamics of crystal growth [21]. Increased extracellular
calcium levels have been shown to drive chondrocyte dif-
ferentiation towards a mineralizing phenotype, while
calcium depletion from culture media maintains a stable
cellular phenotype [35]. GGCX and VKOR are two crucial
enzymes involved in c-carboxylation [13]. Remarkably,
the increase of GRP and MGP expression in OA-derived
cells was associated with a down-regulation of GGCX and
VKOR genes, suggesting a reduced capacity of OA cells,
and consequently a decrease in the c-carboxylation of
target proteins such as GRP and MGP. In fact, we have
previously shown a predominance of ucGRP and ucMGP
in biological OA samples [27]. Moreover, reduced vitamin
K-dependent c-carboxylase activity has been reported in
OA chondrocytes and correlated with (1) decreased c-
carboxylation of MGP and (2) increased matrix mineral-
ization [36]. Although the triggers for articular cartilage
calcification associated with OA are still not completely
understood, dysregulation of mineral metabolism such as
calcium and phosphate and an imbalance in the production
of mineralization inhibitors are crucial factors favoring
cartilage calcification and deposition of calcium-containing
crystals, such as BCPs. It should be noted that these factors
that trigger articular calcification are important to avoid
chondrocyte phenotype alterations such as hypertrophic
differentiation, apoptosis, as well as altered responses to
inflammatory cytokines and mediators of inflammation
Fig. 5 Effect of GRP in ECM mineral deposition in chondrocytes
and synoviocytes. Mineralization rate was determined by calcium
measurement (normalized to protein levels) after 3 weeks of NHAC
and HFLS cells treatment with 5.4 mM CaCl2 (Ca), or supplemented
with 500 ng/mL of ucGRP (Ca?ucGRP) or cGRP (Ca?cGRP).
Control corresponds to cells cultured in non-supplemented media.
Data are representative of three independent experiments. Ordinary
one-way ANOVA was performed. Statistical significance was defined
as P B 0.05 (*)
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[37]. Interestingly, we also showed that synoviocytes were
able to produce a mineralized ECM with up-regulation of
OC and OPN, and down-regulation of vimentin, suggesting
a possible contribution of synoviocytes to the production of
BCPs in OA articular joint. BCPs have been shown to play
an important role in the onset and progression of OA [5],
and are considered to be early phenomena affecting the
whole joint, occurring even before any evidence of
cartilage breakdown [4]. BCPs have been found in the
synovial fluid, synovial membrane and cartilage from OA
patients [4, 6, 7], and are currently considered a damage-
associated molecular pattern (DAMP). The underlying
mechanism is thought to be the signaling to the immune
system a state of stress [8], and potentially contributing to
OA-associated inflammation through stimulation of artic-
ular cells [6, 7]. Besides their effect on synoviocyte
Fig. 6 In vitro and in vivo studies of GRP association with
inflammatory events in osteoarthritis. a Gene expression of COX2
and MMP13 over 3 weeks of mineralizing treatment (5.4 mM
calcium) in NHAC and HFLS (each week a set point, T0–T3).
Values of gene expression are relative to the reference sample (T0)
and set to 1. Data are representative of three independent experiments.
Two-way Anova and multiple comparisons were achieved with the
Tukey’s test. Statistical significance was defined as P B 0.05 (*) and
P B 0.005 (**). b Gene expression levels of COX2, MMP13 and
GRP in NHAC and HFLS cells, after 72-h inflammatory stimulation
with 5 ng/mL IL-1b. Values are relative to the reference sample (0 h).
Data are representative of three independent experiments. Two-way
Anova and multiple comparisons were achieved with the Tukey’s test.
Statistical significance was defined as P B 0.05 (*). c–f Immunode-
tection of CD45, showing leucocyte infiltration sites (c and d) and
total GRP (e and f, CTerm-GRP antibody) in consecutive sections of
osteoarthritic synovial membrane samples. Counterstaining with HE;
sale bar represents 100 lm
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proliferation, along with production of inflammatory
cytokines, MMPs and prostaglandins, BCP crystals also
induce articular chondrocytes to produce prodegradative
soluble factors such as nitric oxide and to undergo apop-
tosis [5, 7, 8]. Production of MMPs and chondrocyte
apoptosis contributes to cartilage destruction, while
Fig. 7 Effect of GRP in the inflammatory process promoted by the
addition of BCP crystals to articular cells. a Gene expression of
COX2 and MMP13 in NHAC and HFLS cells supplemented for 72 h
with BCP crystals (BCP) or BCPs coated with ucGRP
(BCP ? ucGRP) or cGRP (BCP ? cGRP). Values are relative to
the reference sample (untreated cells 0 h). Data are representative of
three independent experiments. Two-way Anova and multiple
comparisons were achieved with the Tukey’s test. Statistical signif-
icance was defined as P B 0.05 (*), P B 0.005 (**) and P B 0.0005
(***). b PGE2 accumulation in NHAC and HFLS conditioned media
of cells treated for 72 h as described in a. Control corresponds to
culture media of non-treated cells. Ordinary one-way ANOVA was
performed. Statistical significance was defined as P B 0.05 (*),
P B 0.005 (**) and P B 0.0005 (***)
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Fig. 8 Effect of GRP in chondrocytes and synoviocytes under
in vitro inflammatory conditions mimicking osteoarthritis. a Gene
expression of COX2 and MMP13 in NHAC and HFLS cells pre-
treated with 500 ng/mL of ucGRP or cGRP or 2 lM dexamethasone
(DXM) followed by IL-1b stimulation (5 ng/mL) during 72 h. Cells
untreated with GRP or DMX were also analyzed (IL-1b). Control
corresponds to cells grown in advanced DMEM only. Values are
relative to the reference sample (0 h). Data are representative of three
independent experiments. Two-way Anova and multiple comparisons
were achieved with the Tukey’s test. Statistical significance was
defined as P B 0.05 (*), P B 0.005 (**) and P B 0.0005 (***).
b PGE2 accumulation in cell media of NHAC and HFLS treated for
24 h as described in (a). Control corresponds to culture media of non-
treated cells. Ordinary one-way ANOVA was performed. Statistical
significance was defined as P B 0.05 (*), P B 0.005 (**) and
P B 0.0005 (***)
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cartilage degradation products drive inflammatory events
in a pathological mineralization–inflammation tissue
degradation cycle [5, 7]. To unveil the role of GRP in the
mineralization–inflammation processes associated with
OA, we decided to investigate the effect of GRP-induced
modulation of inflammatory conditions triggered by a
mineralization stimulus. COX2 and MMP13 up-regulation
was observed during mineralization in chondrocytes and
synoviocytes and confirmed that calcification can stimulate
proinflammatory signaling that parallels cell differentia-
tion, whereas calcification is also accompanied by an up-
regulation of GRP expression. These results reinforce the
concept that also other cells of the joint, including fibrob-
last-like synoviocytes and chondrocytes, directly contribute
to the innate immune activation and cytokine production in
OA [8]. Moreover, the concomitant increase in GRP
expression with inflammation, triggered by mineralization
conditions, indicates a calcium-mediated role for GRP in
the inflammatory processes. However, our experiments
also showed increased GRP expression after inducing
inflammation with IL-1b, with a highly similar pattern to
the inflammatory markers COX2 and MMP13. These
results suggest that the involvement of GRP in inflamma-
tory-mediated processes might not be exclusively mediated
by mineralization events, opening new perspectives for
GRP as a novel cross-talk factor linking calcification and
inflammation processes occurring in articular cells that
should become highly relevant for the study of OA
development and progression.
As previously reported, GRP is able to bind BCP crys-
tals in vitro and the calcification inhibitory function of GRP
might be through modulation of crystal formation and/or
growth [21]. Moreover, BCPs have been suggested to have
a direct pathogenic role in OA, driving synovial inflam-
mation and cartilage degradation [5]. Based on these facts,
we decided to further investigate the potential role of GRP
in the inflammatory response mediated by BCPs in the
articular cell system. Our results clearly demonstrate that
coating BCP crystals with GRP reduces its proinflamma-
tory effect, protecting cells from the increased expression
of MMP13 and PGE2 production. It has been proposed that
calcium-containing crystals may activate articular cells by
either leading to an increase in intracellular calcium levels
after crystal endocytosis or phagocytosis, with consequent
intralysosomal crystal dissolution, through direct crystal-
cell membrane interaction, that may occur via electrostatic
bonds with the naked crystal surface, or by membrane
receptor stimulation with naked or protein-coated crystals
[37]. Although the mechanisms behind a GRP-BCP
mediated anti-inflammatory effect in articular cells are
currently unknown, we speculate that GRP binding to BCP
will probably interfere with crystal–cell membrane inter-
action, thus modulating the production of proinflammatory
mediators. It is interesting to note that, compared with
naked hydroxyapatite crystals, fetuin-A-containing cal-
ciprotein particles (CPP), well known for their role in the
prevention of uncontrolled mineralization, were recently
reported to decrease cytokine production in macrophages
[38]. Moreover, serum-derived CPP have been shown to
produce a higher protective effect than synthetic CPP in
macrophage activation [38], probably reflecting the inhi-
bitory activity of other serum components, such as GRP.
We have recently shown an association between GRP,
fetuin-A and MGP at sites of aortic valves calcification,
and proposed that the calcification inhibitory function of
GRP may occur constitutively via this potent inhibitory
system formed by proteins with strong calcium phosphate
binding capacity [21]. Furthermore, pre-treatment of
chondrocytes and synoviocytes with GRP followed by IL-
1b stimulation mirrored the anti-inflammatory effect
observed with GRP-coated BCPs. This is consistent with
an anti-inflammatory role by down-regulation of cytokines
and MMPs production, in some cases at levels comparable
to DXM. Interestingly, the anti-inflammatory-mediated
effect of GRP was apparently independent of its c-car-
boxylation status, suggesting additional functions for
undercarboxylated GRP. Although undercarboxylated
VKDPs are generally regarded as non-functional and
related to pathological states [32, 39], decreased c-car-
boxylation of OC has been implicated in the regulation of
energy metabolism, with novel metabolic roles [40]. This
area is still under debate, however, and whether carboxy-
lated or uncarboxylated osteocalcin acts as the active
hormone in energy metabolism remains to be clarified.
Moreover, in the past decade, vitamin K biological func-
tions other than acting as a coenzyme of GGCX have been
proposed, namely the anti-inflammatory effect of vitamin
K2 through suppression of the NF-kB pathway with a dual
pro-anabolic and anti-catabolic activity in bone [41]. In
fact, inappropriate regulation of anti-catabolic activity in
bone has been shown as one of the major causes of setting
an inflammatory state in both OA and rheumatoid arthritis
[42]. Although we have shown in this work that GRP is
associated to inflammation in osteoarthritic synovial
membrane undergoing synovitis, a process characterized
by lymphocytes and plasma cells infiltration [43], its
involvement in immune cells inflammatory responses is
presently unclear. Also, additional characterization of the
anti-inflammatory activity of GRP and correlation with c-
carboxylation status is necessary to further unveil the
molecular pathways involved.
Overall, we propose that in a context of OA with
induced cell differentiation and ECM calcification, the
increased expression of VKDPs such as GRP and MGP
might function to counteract calcification. However, sys-
tem overload could lead to hampered c-carboxylation
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capacity resulting in increased levels of undercarboxylated
GRP, which might contribute to control the levels of
inflammatory mediators through still unknown mecha-
nisms, and thereby protecting the joint structures from
damage. Moreover, our results have shown that the effects
of GRP in both calcification and inflammation processes
were similar in control and OA-derived cell cultures,
indicating that GRP can exert its function as calcification
inhibitor and mediator of inflammation at different OA
stages. Therefore, it is a potential candidate for therapeutics
in OA, acting at both calcification and inflammation
processes.
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